Design Therapeutics (DSGN) Downgraded by Zacks Investment Research to Sell

Design Therapeutics} stock has undergone multiple analysts rating changes in the recent past.  Design Therapeutics Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More Design Therapeutics (DSGN) Downgraded by Zacks Investment Research to Sell